liver metastasis

Ki16198 is an orally available LPA receptor antagonist and is a methyl ester derivative of Ki16425. It inhibits LPA1- and LPA3-induced inositol phosphates with Ki values of 0.34 and 0.93 μM, respectively, and can be used in studies of pancreatic carcinogenesis and metastasis.

RO-3306 is a selectivity ATP-competitive CDK1 inhibitor (Ki: 20 nM). The selectivity of RO-3306 for CDK1 is >15-fold higher than a diverse panel of human kinases.

Selvigaltin (GB1211) is an orally administered, highly selective small-molecule inhibitor of galectin-3 (Gal-3) with an IC₅₀ value of 12 nM in rabbits, exhibiting anticancer and anti-fibrotic activity. Selvigaltin reduces galectin-3 levels in the liver and decreases biomarkers of inflammation (cellular foci) and fibrosis (PSR, SHG), while simultaneously lowering the mRNA and protein expression of inflammatory and fibrotic biomarkers (IL-6, TGF-β3, SNAI2, collagen). Selvigaltin also restores T-cell activity and reduces tumor growth and metastasis. Selvigaltin is suitable for use in studies of liver fibrosis, non-alcoholic steatohepatitis (NASH), and tumors.

Glabridin (KB-289522) may serve as an anti-inflammatory agent in diabetes-related vascular dysfunction, through regulating the synthesis and activity of iNOS under high-glucose levels; may possess a therapeutic effect on metabolic disorders( such as diabetes and hyperglycemia), by modulating glucose metabolism through AMPK in skeletal muscle cells. Glabridin may have potential as a chemopreventive agent against liver Y metastasis, by inhibiting the invasion of human HCC cells.

CWP232228, a potent and selective Wnt / β-catenin signaling inhibitor, antagonizes the binding of β-catenin to T-cell factor (TCF) in the nucleus. CWP232228 inhibits the formation and metastasis of tumors by inhibiting the growth of breast cancer and live

Benzyl-α-GalNAc (O-glycosylation-IN-1) is an effective inhibitor of O-glycosylation used to reduce the levels of mucin on the cell surface; it can inhibit the synthesis of O-glycosylated mucin in a human pancreatic cancer cell model. Benzyl-α-GalNAc effectively inhibits the proliferation and activation of LX-2 cells and suppresses the expression of collagen I/III, making it suitable for studies on liver fibrosis. Benzyl-α-GalNAc can be used in research on glycobiology, tumor metastasis, liver fibrosis, and chemotherapeutic sensitization.

PTUPB is a potent dual inhibitor of sEH and COX-2 enzymes with IC50 values of 0.9 nM and 1.26 μM, respectively.

Gadoxetate Disodium is used to evaluate focal liver lesions, such as hepatocellular carcinoma or liver metastasis on T1-weighted imaging. It is a contrast agent in magnetic resonance imaging (MRI) of the hepatobiliary system. It accumulates in normal, fun

HYL001 (compound 338) is a potent inhibitor of the TGFβ receptor 1 (ALK5), exhibiting approximately nine times the efficacy of its structurally related counterpart, galunisertib, in eliminating liver metastasis tumors generated in mice.

PX20350 is an FXR agonist with EC50 values of 83 nM for mFXR and 10 nM for hFXR. It significantly induces NDRG2 mRNA expression. PX20350 effectively inhibits the growth and metastasis of liver tumor cells (SK-GI-18 cells) and exhibits antitumor activity in orthotopic xenograft mouse models.

RMC-9945 (RM-044) is a KRAS inhibitor that is selective, covalent, and orally active against the RAS(ON) G12D mutation. It enhances the transcriptional activity of β-Catenin/TCF and demonstrates sustained disease control in early liver metastasis models of colorectal cancer.

SU212 is a podophyllotoxin-derived ENO1 inhibitor and AMPK activator. It selectively induces oxidative phosphorylation in cells, reduces glycolytic activity and glucose uptake in tumor cells, and directly binds ENO1 without affecting pathways in normal cells. SU212 induces apoptosis and facilitates ENO1 degradation via proteasomal and autophagic pathways without inhibiting its catalytic activity. It activates AMPK independently of energy stress and without being affected by glucose or insulin levels, resulting in M phase arrest and apoptosis in triple-negative breast cancer (TNBC) cells, demonstrating potent in vitro antitumor activity. Additionally, SU212 inhibits tumor growth and metastasis in syngeneic, xenograft, and diabetic mouse models, showing excellent safety profiles. This compound can be utilized in research on TNBC, diabetes, and fatty liver disease.

Multi-target kinase-IN-9 is a multi-target enzyme inhibitor with antiproliferative and antiangiogenic activity, showing significant selectivity for liver cancer cells. By extensively binding to active sites or ATP-binding regions of several key enzymes, such as DNA polymerase β and pyruvate kinase M2 (PKM2), it disrupts DNA repair and replication, glycolysis, chromatin dynamics, and transcriptional programs, blocking cancer stem cell self-renewal. This compound induces genomic instability, lysosomal dysfunction, and autophagic flux interruption, leading to tumor cell death. It effectively inhibits tumor proliferation, invasion, metastasis, and angiogenesis, significantly reducing tumor volume in xenograft models. Multi-target kinase-IN-9 is applicable in liver cancer research.

Ganglioside GD1a is a sialic acid-containing glycosphingolipid found in brain, erythrocytes, bone marrow, testis, spleen, and liver. [1] It can be shed from the surface of tumor cells into the microenvironment where it influences tumor-host cell interactions to promote tumor cell proliferation, invasion, and metastasis. Ganglioside GD1a (20 μM) also increases endothelial cell proliferation. Furthermore, ganglioside GD1a has been shown to act as a functional coreceptor for toll-like receptor 2 (TLR2), enabling the recruitment of TLR2 to lipid rafts when bound by a bacterial toxin.[2] Ganglioside GD1a mixture contains ganglioside GD1a molecular species with C18:1 and C20:1 sphingoid backbones.

Ajoene is a disulfide that has been found inA. sativumand has diverse biological activities, including antibacterial, anticancer, antiplatelet, and antioxidant properties.1,2,3,4It is active against Gram-positive (MICs = 5-160 µg/ml) and Gram-negative bacteria (MICs = 136-200 µg/ml), as well as yeasts (MICs = 10-20 µg/ml).1Ajoene is cytotoxic to mouse melanoma cells (IC50= 18 µM), as well as human colon, lung, mammary, and pancreatic cancer cells (IC50s = 7-41 µM).2It reduces tumor growth in a B16/BL6 mouse model of melanoma when administered at a dose of 25 mg/kg every other day and decreases the number of lung metastases when administered prior to tumor cell inoculation at doses ranging from 1-25 mg/kg. It inhibits ADP- or collagen-induced platelet aggregation in isolated baboon platelets when used at concentrations ranging from 75 to 150 µg/ml and in platelet-rich plasma isolated from baboons when administered at a dose of 25 mg/kg.3Ajoene (25 mg/kg) prevents thrombus formation on damaged arterial walls in heparinized pigs in anin situmodel of thrombogenesis.5It also reduces high-fat diet-induced hepatic steatosis, histopathological markers of liver damage, thiobarbituric acid reactive substances (TBARS) formation, and protein oxidation in a mouse model of non-alcoholic fatty liver disease (NAFLD).4 1.Naganawa, R., Iwata, N., Ishikawa, K., et al.Inhibition of microbial growth by ajoene, a sulfur-containing compound derived from garlicAppl. Environ. Microbiol.62(11)4238-4242(1996) 2.Taylor, P., Noriega, R., Farah, C., et al.Ajoene inhibits both primary tumor growth and metastasis of B16/BL6 melanoma cells in C57BL/6 miceCancer Lett.239(2)298-304(2006) 3.Teranishi, K., Apitz-Castro, R., Robson, S.C., et al.Inhibition of baboon platelet aggregation in vitro and in vivo by the garlic derivative, ajoeneXenotransplantation10(4)374-379(2003) 4.Han, C.Y., Ki, S.H., Kim, Y.W., et al.Ajoene, a stable garlic by-product, inhibits high fat diet-induced hepatic steatosis and oxidative injury through LKB1-dependent AMPK activationAntioxid. Redox Signal.14(2)187-202(2011) 5.Apitz-Castro, R., Badimon, J.J., and Badimon, L.A garlic derivative, ajoene, inhibits platelet deposition on severely damaged vessel wall in an in vivo porcine experimental modelThromb. Res.75(3)243-249(1994)

Selachyl alcohol is an orally active antihypertensive agent with activities similar to antihypertensive neutral renomedullary lipid (ANRL). As an alkylglycerol compound in shark liver oil mixtures, it possesses lung metastasis-inhibiting properties and can be used for cardiovascular disease research.

TT-012 has anti-tumor activity, selectively binds dynamic MITF and disrupts the dimer formation and DNA binding of the latter. TT-012 can inhibit the transcription of MITF in B16F10 melanoma cells. TT-012 inhibited the growth and metastasis of MITF melanoma cells in animal models. TT-012 is less cytotoxic to liver and immune cells.

Tubulin/HDAC-IN-2 (Compound II-19k) is a dual inhibitor of Tubulin and HDAC, with IC50 values of 0.403 μM for HDAC1, 0.591 μM for HDAC2, 3.552 μM for HDAC3, and 0.459 μM for HDAC6. The compound induces G2 phase cell cycle arrest, promotes apoptosis, hampers hematoma and solid tumor cell proliferation, diminishes tumor metastasis, and inhibits tumor growth in a liver tumor allograft mouse model [1].

6-methyl-2-[2-[(E)-(6-oxo-1-cyclohexa-2,4-dienylidene)methyl]hydraziny l]-1H-pyrimidin-4-one (NSC 73150) is a pyrimidine derivative with antitumor activity. Preclinical studies have shown that it inhibits the growth of a variety of tumor cell lines, including breast, lung, and liver cancers. It has also been found to induce apoptosis, inhibit angiogenesis and suppress tumor metastasis.

Glabridin (Standard) is a reference standard for research and analysis in studies involving Glabridin. Glabridin (KB-289522) may serve as an anti-inflammatory agent in diabetes-related vascular dysfunction, through regulating the synthesis and activity of iNOS under high-glucose levels; may possess a therapeutic effect on metabolic disorders( such as diabetes and hyperglycemia), by modulating glucose metabolism through AMPK in skeletal muscle cells. Glabridin may have potential as a chemopreventive agent against liver Y metastasis, by inhibiting the invasion of human HCC cells.

Cudratricusxanthone A has potent anti-proliferative, antioxidative, and monoamine oxidase inhibitory effects, it also possesses anti-cancer activities and provide a basis for developing effective therapeutic agents to inhibit growth and metastasis of brea